4 citations
,
December 2024 in “Archives of Dermatological Research” 63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
49 citations
,
October 2023 in “Journal of Dermatological Science” 
1 citations
,
January 2023 in “Przegląd Dermatologiczny” This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
8 citations
,
August 2018 in “International Journal of Dermatology” This study discusses the prevalence and ethical considerations of off-label drug use in dermatology, emphasizing differing perspectives on informed consent between patients and physicians.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
17 citations
,
March 2018 in “Pediatric dermatology” This study suggests that hydroxychloroquine may benefit some children with alopecia areata, as five out of nine patients showed improvement, although side effects like gastrointestinal intolerance and headache were noted.
10 citations
,
January 2018 in “International Journal of Trichology” In this study, researchers retrospectively analyzed five children with extensive and refractory alopecia areata treated with mesalazine, observing complete hair regrowth in all patients without side effects, suggesting potential benefits of this treatment combination, though controlled studies are needed for confirmation.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
22 citations
,
June 2017 in “Journal of dermatological treatment” This case series observed that 57% of pediatric patients with alopecia areata experienced significant hair regrowth with methotrexate treatment, which was generally safe, although some results were inconclusive due to follow-up issues.
9 citations
,
April 2016 in “Australasian journal of dermatology” This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.
14 citations
,
January 2016 in “Annals of dermatology/Annals of Dermatology” This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.
49 citations
,
November 2013 in “JAMA dermatology” This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.
37 citations
,
September 2012 in “Archives of dermatology” Diphencyprone can help some children with alopecia areata regrow hair, but it often causes side effects.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.
